# Pradeep B Lukka

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1453798/publications.pdf

Version: 2024-02-01

| 17 | 146 | 1464605 7 | 1526636 10 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 18 | 18 | 18 | 167 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2022, 21, 1103-1114. | 1.9 | 5 |
| 2 | Discovery of N-(3,4-Dimethylphenyl)-4-(4-isobutyrylphenyl)-2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinoline-8-sulfonamide as a Potent Dual MDM2/XIAP Inhibitor. Journal of Medicinal Chemistry, 2021, 64, 1930-1950. | 2.9 | 10 |
| 3 | Use of Realâ€World Data and Pharmacometric Modeling in Support of Lacosamide Dosing in Pediatric Patients Under 4 Years of Age. Journal of Clinical Pharmacology, 2021, 61, 881-888. | 1.0 | 9 |
| 4 | Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0174420. | 1.4 | 7 |
| 5 | X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor. Journal of Medicinal Chemistry, 2021, 64, 13072-13095. | 2.9 | 13 |
| 6 | Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis. ACS Infectious Diseases, 2021, 7, 2850-2863. | 1.8 | 8 |
| 7 | Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599. Pharmaceutical Research, 2019, 36, 136. | 1.7 | 19 |
| 8 | Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice. Tuberculosis, 2019, 114, 119-122. | 0.8 | 8 |
| 9 | Sterilization of Mycobacterium tuberculosis infected samples using methanol preserves anti-tuberculosis drugs for subsequent pharmacological testing studies. Tuberculosis, 2019, 117, 52-55. | 0.8 | 2 |
| 10 | Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis. Frontiers in Microbiology, 2018, 9, 1895. | 1.5 | 5 |
| 11 | Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells. PLoS ONE, 2017, 12, e0172628. | 1.1 | 15 |
| 12 | Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent. Cancer Chemotherapy and Pharmacology, 2014, 74, 25-35. | 1.1 | 8 |
| 13 | Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent. Cancer Chemotherapy and Pharmacology, 2013, 72, 1013-1022. | 1.1 | 4 |
| 14 | Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics. Cancer Chemotherapy and Pharmacology, 2012, 70, 151-160. | 1.1 | 8 |
| 15 | A rapid LCâ€“MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: Application to in vivo pharmacokinetic and lipophilicity studies in drug development. Journal of Pharmaceutical and Biomedical Analysis, 2012, 63, 9-16. | 1.4 | 7 |
| 16 | Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. Cancer Chemotherapy and Pharmacology, 2010, 65, 1145-1152. | 1.1 | 10 |
| 17 | Development and validation of a liquid chromatographyâ€“mass spectrometry (LCâ€“MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN) Tj ETQq1 1 0.784314 rgBT /O 2008, 875, 368-372. | 1.1 | 3 |